Molecular Formula | C34H54O8 |
Molar Mass | 590.78776 |
Density | 1.119±0.06 g/cm3(Predicted) |
Melting Point | 110-114°; mp 100-109° (unsharp) |
Boling Point | 735.7±60.0 °C(Predicted) |
Storage Condition | Room Temprature |
Physical and Chemical Properties | Bioactive Lasalocid (Lasalocid-A; Ionophore X-537A; Antibiotic X-537A) is an antibacterial and Anticoccidial agent used in feed additives. |
Zhang Suxia , Shen Jianzhong , Ding Shuangyang , Li Xiaowei
Abstract:
A high performance liquid chromatography (HPLC) method was developed for the determination of Lassa Losi sodium residue in chicken liver. The residual Lassa losidic sodium in chicken liver tissue samples was extracted with methanol and purified by silica gel column. The phosphate buffer, acetonitrile and methanol were used as mobile phase and detected by Reversed-phase high performance liquid chromatography with fluorescence detection. The average recovery rate was 82. The average coefficient of variation was 7.75%, and the detection limit was 0.0.2 mg/kg.Key words:
high performance liquid chromatography Lassa loxidate sodium chicken liver tissue residue detection
DOI:
10.3969/j.issn.1002-1280.2004.01.007
cited:
year:
2004
CN201410584940.X
application date:
2014-10-28
Public/Announcement Number:
CN104367548B
Public/announcement date:
2017.02.22
applicant (patent):
Henan Muxiang animal Pharmaceutical Co., Ltd.
inventor:
Li Huifang , Guo Jianjun , Chen
National and provincial code:
CN410184
Abstract:
The present invention relates to a sodium lasalocis microemulsion, which belongs to the technical field of medicine and has an active ingredient of sodium lasalocis and a weight percentage of 0.01-5.0%. The microemulsion has a weight percentage composition of 0.01-5.0% of sodium lasalocis, 0.5-10.0% of an oil phase, 18.0-36.0% of a surfactant, 0-6.0% of a cosurfactant, and the remainder being deionized water. The change in the dosage form of the present invention makes the use of the sodium Lassa more convenient, and the antibacterial effect is significantly increased, and the number of times of administration is reduced.
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.693 ml | 8.463 ml | 16.927 ml |
5 mM | 0.339 ml | 1.693 ml | 3.385 ml |
10 mM | 0.169 ml | 0.846 ml | 1.693 ml |
5 mM | 0.034 ml | 0.169 ml | 0.339 ml |
invention patent
Application (patent) number:
CN201310159816.4
application date:
20130503
Public/Announcement Number:
CN103424479A
Public/announcement date:
20131204
applicant (patent):
Huazhong Agricultural University
inventor:
yuan zonhui , Tao Yanfei , Chen Dongmei , pan yuanhu , Yu-lian wang , Huang Lingli , Wang Xu , Liu Zhenli , Xie Shuyu , Dapeng Peng , wearing Dream Red , Hao Haihong , Cheng Gu yue
National and provincial code:
CN420111
Abstract:
The invention belongs to the technical field of veterinary drug residue analysis, and discloses a carboxyl compound Polyether drug hydrogen substitution derivatization reaction high performance liquid chromatography pre-column derivatization reaction analysis method. The Polyether drug contains a carboxyl group and reacts with the fluorescent reagent 1-bromoacetopyrene, and the product has extremely strong fluorescent activity. The optimized reaction conditions were as follows: 18-crown ether -6 solution as phase transfer catalyst, 1-bromoacetopyrene solution as derivatization reagent, water bath at 30-70 ℃ for 150min, after cooling, the derivative product has the maximum fluorescence intensity at the excitation wavelength of 360nm and the emission wavelength of 420nm, and the minimum detectable amount is 50 μg/L, linear response to peak area in the range of 200~1600 μg/L, the results showed good reproducibility, and the coefficient of variation of 3 concentrations and 15 repeats was less than 7.8%, all the indexes can meet the requirements of the analysis of monensin, salinomycin and lassaloxine three kinds of Polyether drug residues.